BillionToOne, Inc. · Medical Laboratories

BLLN

Low riskNext report: Around Dec 8 (est.)

View price ↗

The short version

A profitable company with growing sales. Institutions are adding.

Going well

Sales up 64% in the latest quarter vs a year ago
Profitable
Sales up 100% last year

Money moves

Insiders sold $6.7M in the last 30 days, all through pre-planned sales
Institutions added 35% to their holdings in the quarter ending June 2026 (126 bought, 24 sold)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$111.46+3.5% that day

Company value: $6.1B; Share price times all shares
Price vs profit (P/E): 159.2x; You pay about $159 for each $1 of yearly profit
Price vs sales: 15.3x; Company value is 15.3 times a year of sales
Cash vs value: 9%; Cash as a share of company value
Debt vs value: 1%; Debt as a share of company value

From BLLN's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 8 quarters, from SEC filings

Sales, Jun '26

$109.4M+64% vs a year earlier

Sep '24Tap a barJun '26

Last 12 months: $397.4M, up 90% from the 12 months before.

What the price assumes

Your guesses, our math

Move the sliders to your own view of BLLN. Starting points are the company's recent numbers.

Sales growth+30% a yearRecently: +90% a yearProfit margin9%Last 12 months: 9.5%P/E at the end40xToday: 159.2x. Many steady companies trade at 12x to 25xShare count change0% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$1.5B

Profit in 5 years$133M

Price these guesses point to$97.55-12% vs $111.46 todayAbout -2.6% a year, before dividends

What today's price needs: with a 9% margin and a 40x P/E, sales would have to grow about 34% a year for 5 years just to match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

3/5Mixed

MissReturn on equity 15%+Earns a lot on the money owners have in the business.6.5%
PassDebt under half of equityNot relying on borrowed money.0.12x equity
MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.2.4%
PassFree cash flow positiveBrings in more cash than it spends to run and grow.$15.7M
PassGross margin 40%+Pricing power: sells for well above what it costs to make.68.3%

Revenue: $305.1M; +100.0% vs prior year
Total debt: $57.2M; 0.12x equity
Current ratio: 11.69x; short-term assets / bills due
Free cash flow: $15.7M; 5.2% of revenue

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: profitable every year, share count not growing. A checklist is a starting point for research, not a verdict.

Latest quarter

Quarter ended Jun 30, 2026

Reported Aug 5

Revenue: $109.4M; +64.4% YoY
EPS: $0.15; vs -$0.02
Op. margin: 5.0%; +7.4 pts
Gross margin: 70.5%; +5.2 pts
Free cash flow: $5.1M
Share count: +424.4%; vs a year ago

Insider rating

Last 90 days

43Mixed

Pre-planned sales of $7.3M (weaker signal)

50 is neutral. Buying by more insiders, top executives and bigger stakes raises it. Selling lowers it; pre-planned sales count less.

Weekly insider trend

13 weeks agoBoughtSoldThis week

Filing buzz

Last 7 days vs normal

0/ 100

This week: 0
Normal week: 4.6
vs normal: 0.0x

SEC filings of any kind. 50 means a normal week.

Institutional ownership

Accumulating+34.6%

Institutions added 34.6% to their holdings. 126 bought, 24 sold. 3 quarters of net buying in a row.

Shares held by institutions15.3M

Sep '24Jun '26

Safety check

From SEC filings

Cash runwayAt last year's cash burn

Cash flow positive

Debt to equityLatest balance sheet: debt compared with what owners have

0.2x · $91.0M debt

Shares outstandingLatest reported

54M

Earnings reports

Last 5

Next reportAround Dec 8 (est.)Estimated from the same quarter last year

Results filedAug 5
Results filedMay 6
Results filedMar 4
Results filedJan 12
Results filedDec 9, 2025

Flags and big holders

Offerings 6 months, flags 12 months, holders 90 days

No offerings, red flags or new big holders. Clean record.

Insider trades

Open-market buys and sells, last 90 days

Bought$00 insiders

Sold$7.3M3 insiders, 7 pre-planned

Insider	Trade	Shares	Avg price	Value	Owns after	Date
Oguzhan AtayChairman and CEO	Sell	11K	$99.14	$1.1M	0	Oct 15Filing ↗
Sold entire stake $98.00 to $102.78 across 8 trades Traded Oct 14 to Oct 15 Held via spouse Pre-planned sale (10b5-1) Also Director Filed 1 day after
Oguzhan AtayChairman and CEO	Sell	19K	$94.31	$1.8M	152K	Oct 12Filing ↗
-11.3% of their holdings $91.57 to $97.61 across 6 trades Held via spouse Pre-planned sale (10b5-1) Also Director Filed 2 days after
David TsaoChief Technology Officer	Sell	20K	$108.15	$2.2M	1K	Oct 5Filing ↗
-95.2% of their holdings $105.56 to $110.09 across 11 trades Pre-planned sale (10b5-1) Also Director Filed 2 days after
Bosch John Roderick TenSVP of Laboratory Operations	Sell	3K	$105.15	$298K	19K	Oct 5Filing ↗
-12.8% of their holdings 2 trades Pre-planned sale (10b5-1) Filed 2 days after
Oguzhan AtayChairman and CEO	Sell	11K	$120.64	$1.3M	155K	Sep 28Filing ↗
-6.6% of their holdings 2 trades Held via spouse Pre-planned sale (10b5-1) Also Director Filed 2 days after
David TsaoChief Technology Officer	Sell	3K	$125.00	$417K	1K	Sep 24Filing ↗
-76.9% of their holdings Pre-planned sale (10b5-1) Also Director Filed 4 days after
Bosch John Roderick TenSVP of Laboratory Operations	Sell	1K	$120.00	$170K	22K	Sep 24Filing ↗
-6% of their holdings Pre-planned sale (10b5-1) Filed 4 days after